公开(公告)号：US06426192B1

公开(公告)日：2002-07-30

申请号：US09403805

申请日：2000-01-19

Applicant: Kurt Stocker ,  Patrizia Gempeler-Messina ,  Christian Müller

Inventor： Kurt Stocker ,  Patrizia Gempeler-Messina ,  Christian Müller

IPC: C12Q156

CPC classification number: G01N33/86 ,  G01N2333/4626 ,  G01N2333/96461 ,  G01N2333/96463 ,  G01N2400/40 ,  Y10S435/975

Abstract: The method relates to a method for detecting disorders in the protein C system, and in particular for determining the activated blood coagulation factor V with increased stability with respect to decomposition by activated protein C.

Abstract translation: 该方法涉及一种用于检测蛋白质C系统中的疾病的方法，特别是用于通过活化的蛋白质C分解增加的稳定性来确定活化的血液凝固因子V.

公开(公告)号：US5869238A

公开(公告)日：1999-02-09

申请号：US390904

申请日：1995-02-16

Applicant: Dennis R. Morrison

Inventor： Dennis R. Morrison

IPC: C12Q1/68 ,  G01N33/573 ,  G01N33/574 ,  G01N33/48

CPC classification number: G01N33/57492 ,  C12Q1/6886 ,  G01N33/573 ,  G01N33/57496 ,  C12Q2600/112 ,  G01N2333/723 ,  G01N2333/96463

Abstract: The metastatic potential of tumors can be evaluated by the quantitative detection of urokinase and DNA. The cell sample selected for examination is analyzed for the presence of high levels of urokinase and abnormal DNA using analytical flow cytometry and digital image analysis. Other factors such as membrane associated urokinase, increased DNA synthesis rates and certain receptors can be used in the method for detection of potentially invasive tumors.

Abstract translation: 可以通过尿激酶和DNA的定量检测来评估肿瘤的转移潜能。 使用分析流式细胞术和数字图像分析，分析选择用于检查的细胞样品中存在高水平的尿激酶和异常DNA。 其他因素如膜相关尿激酶，增加的DNA合成速率和某些受体可用于检测潜在侵袭性肿瘤的方法。

公开(公告)号：US5834223A

公开(公告)日：1998-11-10

申请号：US993664

申请日：1997-12-18

Applicant: John H. Griffin ,  Samuel I. Rapaport ,  Dzung T. Le

Inventor： John H. Griffin ,  Samuel I. Rapaport ,  Dzung T. Le

IPC: G01N33/86 ,  C12Q1/56 ,  C12Q1/00 ,  G01N33/00 ,  G01N33/53

CPC classification number: G01N33/86 ,  G01N2333/745 ,  G01N2333/96461 ,  G01N2333/96463 ,  G01N2400/40 ,  G01N2405/04 ,  Y10S435/81 ,  Y10S435/975

Abstract: The present invention provides an in vitro method useful for the diagnosis of a thrombotic disorder in a subject, having or at risk of having the disorder. Specifically, the disorder exemplified herein is associated with APC resistant Factor V and Va. The clotting time of a test sample is analyzed in the presence and absence of APC and compared with a standard reference sample in order to diagnose the subject.

公开(公告)号：US5610024A

公开(公告)日：1997-03-11

申请号：US412854

申请日：1995-03-29

Applicant: Gert Muller-Berghaus ,  Bernd Potzsch ,  Christoph Seelig

Inventor： Gert Muller-Berghaus ,  Bernd Potzsch ,  Christoph Seelig

IPC: G01N33/53 ,  C07K16/36 ,  G01N33/86 ,  G01N33/92 ,  G01N33/96 ,  C12Q1/56

CPC classification number: G01N33/92 ,  G01N33/86 ,  G01N2333/755 ,  G01N2333/96461 ,  G01N2333/96463

Abstract: In order to determine lupus anticoagulant (LA) antibodies in blood, plasma or tissue samples by means of the inhibitory effect of these antibodies on the neutralizing effect of protein C on the blood coagulation system, a defined amount of activated protein C is added to the sample, after incubation the remaining amount of a physiological substrate of protein C or protein S activity in the sample is determined according to known methods and the amount of LA antibodies present is calculated by comparison with a standard containing no LA antibodies. The method according to the present invention can be used to diagnose a predisposition to thrombotic events or disease-dependent risk of thrombosis as well as to monitor a therapy.

Abstract translation: 为了通过这些抗体对蛋白C对凝血系统的中和作用的抑制作用，在血液，血浆或组织样品中测定狼疮抗凝血（LA）抗体，将定义量的活化蛋白C加入到 样品中孵育后，根据已知方法测定样品中剩余量的蛋白质C或蛋白S活性的生理底物，并通过与不含LA抗体的标准进行比较来计算存在的LA抗体的量。 根据本发明的方法可用于诊断血栓形成事件的倾向或血栓形成的疾病依赖性风险以及监测治疗。

公开(公告)号：US09903877B2

公开(公告)日：2018-02-27

申请号：US14866266

申请日：2015-09-25

Applicant: Abbott Point of Care Inc.

Inventor： Tian-Xian Zhao ,  Anjulia Chiu-Yuk Wong ,  Glenn Brian Martin ,  Katrina Petronilla Di Tullio ,  Isabelle Louisette Thibodeau ,  Steven Roy Breeze ,  Smitha R K Sutrala ,  Eric Hong ,  Sheila Diane Ball

IPC: C12Q1/56 ,  G01N33/86 ,  B01L3/00

CPC classification number: G01N33/86 ,  B01L3/5027 ,  B01L3/502715 ,  B01L2200/04 ,  B01L2200/0605 ,  B01L2200/0684 ,  B01L2200/0689 ,  B01L2200/16 ,  B01L2300/024 ,  B01L2300/027 ,  B01L2300/0636 ,  B01L2300/0645 ,  B01L2300/069 ,  B01L2300/0816 ,  B01L2300/0867 ,  B01L2300/161 ,  B01L2400/0472 ,  B01L2400/0481 ,  B01L2400/0487 ,  B01L2400/0688 ,  G01N2333/96463 ,  G01N2333/974

Abstract: The present invention relates to analytical testing devices including micro-environment sensors and methods for assaying coagulation in a fluid sample applied to the micro-environment sensors, and in particular, performing one or more types of coagulation assays using one or more micro-environment sensors in a single point of care combined test cartridge. For example, the present invention may be directed to test sensor including at least one transducer coated with a polymer layer. The polymer layer comprises a thrombin-cleavable peptide with a detectable moiety.

公开(公告)号：US20160334403A1

公开(公告)日：2016-11-17

申请号：US15159501

申请日：2016-05-19

Applicant: Theranos, Inc.

Inventor： Ian Gibbons ,  Anthony J. Nugent ,  Anthony Delacruz ,  Daniel Young ,  Elizabeth A. Holmes ,  Andrew Drake ,  Timothy Michael Kemp ,  Sunny Balwani ,  Chinmay Pangarkar

IPC: G01N33/569 ,  G01N35/10 ,  B01L3/02

CPC classification number: G01N21/00 ,  B01L3/0275 ,  B01L2300/168 ,  B04B5/0421 ,  C12Q1/42 ,  C12Q1/48 ,  C12Q1/52 ,  C12Q1/6806 ,  C12Q1/6809 ,  C12Q1/689 ,  C12Q2600/158 ,  G01N1/4077 ,  G01N21/0303 ,  G01N21/51 ,  G01N21/59 ,  G01N33/5308 ,  G01N33/54326 ,  G01N33/54393 ,  G01N33/56972 ,  G01N33/56983 ,  G01N33/573 ,  G01N33/74 ,  G01N33/743 ,  G01N33/80 ,  G01N33/82 ,  G01N33/92 ,  G01N35/10 ,  G01N2001/4083 ,  G01N2035/00495 ,  G01N2035/1018 ,  G01N2333/575 ,  G01N2333/62 ,  G01N2333/91188 ,  G01N2333/96463 ,  G06T3/4084 ,  G06T7/0002 ,  G06T7/0012 ,  G06T2207/30004 ,  G06T2207/30168 ,  G16C20/20 ,  H04N5/23222

Abstract: The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

公开(公告)号：US20160187338A1

公开(公告)日：2016-06-30

申请号：US14906620

申请日：2014-07-24

Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Inventor： Douglad Monroe ,  Jen-Yea Chang

IPC: G01N33/573 ,  A61K38/17 ,  A61K38/48

CPC classification number: G01N33/573 ,  A61K38/1722 ,  A61K38/4833 ,  A61K38/4846 ,  A61K38/57 ,  C12Y304/21005 ,  C12Y304/21006 ,  G01N33/502 ,  G01N33/86 ,  G01N2333/96444 ,  G01N2333/96463 ,  G01N2500/00

Abstract: The present invention provides a method of identifying a coagulation inhibitor in a sample, comprising: a) contacting a first portion of the sample with a substrate and thrombin; b) contacting a second portion of the sample with a substrate and a2M-thrombin (thrombin caged in alpha-2-macroglobulin); c) contacting a third portion of the sample with a substrate and coagulation factor Xa; d) contacting a fourth portion of the sample with a substrate and a2M-Xa (factor Xa caged in alpha-2-macroglobulin); and e) assaying for cleavage of the substrate in (a), (b), (c) and (d) above, wherein cleavage of the substrate in (b) and (d) and no cleavage in (a) and (c) identifies heparin in the sample; cleavage of the substrate in (a), (b) and (d) and no cleavage in (c) identifies low molecular weight heparin in the sample; cleavage of the substrate in (a) and (b) and no cleavage in (c) and (d) identifies rivaroxaban in the sample, and cleavage of the substrate in (c) and (d) and no cleavage in (a) and (b) identifies dabigatran in the sample.

Abstract translation: 本发明提供一种鉴定样品中凝固抑制剂的方法，包括：a）使样品的第一部分与底物和凝血酶接触; b）使样品的第二部分与底物和a2M-凝血酶（笼养在α-2-巨球蛋白中的凝血酶）接触; c）将样品的第三部分与基底和凝固因子Xa接触; d）将样品的第四部分与底物和a2M-Xa（α-2-巨球蛋白笼养的因子Xa）接触; 和（e）和（c）中的（b）和（d）中底物的切割， ）鉴定样品中的肝素; （a），（b）和（d）中底物的裂解，（c）中的裂解未证明样品中的低分子量肝素; （a）和（b）中底物的裂解，（c）和（d）中没有裂解鉴定样品中的利伐沙班，（c）和（d）中的底物裂解，（a）和 （b）鉴定样本中的达比加群。

公开(公告)号：US09244073B2

公开(公告)日：2016-01-26

申请号：US14117504

申请日：2012-02-24

Applicant: Paul Q. Hu

Inventor： Paul Q. Hu

IPC: G01N33/53 ,  G01N33/573 ,  C12Q1/37

CPC classification number: G01N33/573 ,  C12Q1/37 ,  G01N2333/96444 ,  G01N2333/96463

Abstract: The present invention relates to method of detecting activity of a sample. Some methods involve detecting a neo-binding-site created by the activity such as detecting an activity of a protease by detecting a neo-binding-site created by cleavage of a substrate by the protease.

Abstract translation: 本发明涉及检测样品活性的方法。 一些方法涉及检测由活性产生的新结合位点，例如通过检测由蛋白酶切割底物产生的新结合位点来检测蛋白酶的活性。

公开(公告)号：US08993604B2

公开(公告)日：2015-03-31

申请号：US13379776

申请日：2010-06-22

Applicant: Chelsea M. Byrd ,  Dongcheng Dai ,  Robert Jordan ,  Dennis E. Hruby

Inventor： Chelsea M. Byrd ,  Dongcheng Dai ,  Robert Jordan ,  Dennis E. Hruby

IPC: A01N43/64 ,  A61K31/41 ,  A01N43/78 ,  A61K31/425 ,  G01N33/574 ,  C12Q1/68 ,  G01N33/68

CPC classification number: G01N33/57434 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/6872 ,  G01N2333/705 ,  G01N2333/82 ,  G01N2333/96463

Abstract: Methods and pharmaceutical compositions for treating viral infections, by administering certain 2-aryl-benzothiazole or 2-heteroaryl-benzothiazole derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

Abstract translation: 公开了通过给予治疗有效量的某些2-芳基 - 苯并噻唑或2-杂芳基 - 苯并噻唑衍生物化合物来治疗病毒感染的方法和药物组合物。 还公开了使用该化合物及其药物组合物的方法。 特别地，公开了由黄病毒引起的病毒感染的治疗和预防，即包括但不限于登革病毒，西尼罗河病毒，黄热病病毒，日本脑炎病毒和蜱传脑炎病毒。

公开(公告)号：US08535898B2

公开(公告)日：2013-09-17

申请号：US12503602

申请日：2009-07-15

Applicant: Qiu-Ping Qin ,  Harri Takalo ,  Allan Milton Byrnard ,  Kirsten Marie Jakobsen

Inventor： Qiu-Ping Qin ,  Harri Takalo ,  Allan Milton Byrnard ,  Kirsten Marie Jakobsen

IPC: A61K38/06 ,  A61K38/07 ,  C12Q1/56 ,  C07K14/745

CPC classification number: C12Q1/56 ,  C07K5/0812 ,  C07K5/101 ,  C07K5/1019 ,  C07K7/02 ,  C07K7/08 ,  C12Q1/37 ,  G01N2333/96463

Abstract: Substrates for thrombin and assays for determining the level of bioactive thrombin in a sample are disclosed, wherein the substrate has the general formula: A-X—Z-A′ wherein one of either A or A′ comprises a luminescent chelate and the other one of A or A′ comprises a first partner of a binding pair, X forms a tri- or tetra-peptide, and Z comprises a linker.

Abstract translation: 公开了用于凝血酶的底物和用于测定样品中生物活性凝血酶水平的测定法，其中底物具有以下通式：AXZA'，其中A或A'中的一个包含发光螯合物，A或A'中的另一个包含 结合对的第一个配偶体，X形成三肽或四肽，Z包含连接体。